Cargando…

Opportunities and challenges in stem cell therapy in cardiovascular diseases: Position standing in 2022

This study intends to evaluate the development, importance, pre-clinical and clinical study evaluation of stem cell therapy for the treatment of cardiovascular disease. Cardiovascular disease is one of the main causes of fatality in the whole world. Though there are great progressions in the pharmac...

Descripción completa

Detalles Bibliográficos
Autores principales: Mahmud, Shabnur, Alam, Safaet, Emon, Nazim Uddin, Boby, Umme Habiba, Kamruzzaman, Ahmed, Firoj, Monjur-Al-Hossain, A.S.M., Tahamina, Afroza, Rudra, Sajib, Ajrin, Marzina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9563042/
https://www.ncbi.nlm.nih.gov/pubmed/36249945
http://dx.doi.org/10.1016/j.jsps.2022.06.017
_version_ 1784808313317228544
author Mahmud, Shabnur
Alam, Safaet
Emon, Nazim Uddin
Boby, Umme Habiba
Kamruzzaman
Ahmed, Firoj
Monjur-Al-Hossain, A.S.M.
Tahamina, Afroza
Rudra, Sajib
Ajrin, Marzina
author_facet Mahmud, Shabnur
Alam, Safaet
Emon, Nazim Uddin
Boby, Umme Habiba
Kamruzzaman
Ahmed, Firoj
Monjur-Al-Hossain, A.S.M.
Tahamina, Afroza
Rudra, Sajib
Ajrin, Marzina
author_sort Mahmud, Shabnur
collection PubMed
description This study intends to evaluate the development, importance, pre-clinical and clinical study evaluation of stem cell therapy for the treatment of cardiovascular disease. Cardiovascular disease is one of the main causes of fatality in the whole world. Though there are great progressions in the pharmacological and other interventional treatment options, heart diseases remain a common disorder that causes long-term warnings. Recent accession promotes the symptoms and slows down the adverse effects regarding cardiac remodelling. But they cannot locate the problems of immutable loss of cardiac tissues. In this case, stem cell treatment holds a promising challenge. Stem cells are the cells that are capable of differentiating into many cells according to their needs. So, it is assumed that these cells can distinguish into many cells and if these cells can be individualized into cardiac cells then they can be used to replace the damaged tissues of the heart. There is some abridgment in this therapy, none the less stem cell therapy remains a hopeful destination in the treatment of heart disease.
format Online
Article
Text
id pubmed-9563042
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-95630422022-10-15 Opportunities and challenges in stem cell therapy in cardiovascular diseases: Position standing in 2022 Mahmud, Shabnur Alam, Safaet Emon, Nazim Uddin Boby, Umme Habiba Kamruzzaman Ahmed, Firoj Monjur-Al-Hossain, A.S.M. Tahamina, Afroza Rudra, Sajib Ajrin, Marzina Saudi Pharm J Review This study intends to evaluate the development, importance, pre-clinical and clinical study evaluation of stem cell therapy for the treatment of cardiovascular disease. Cardiovascular disease is one of the main causes of fatality in the whole world. Though there are great progressions in the pharmacological and other interventional treatment options, heart diseases remain a common disorder that causes long-term warnings. Recent accession promotes the symptoms and slows down the adverse effects regarding cardiac remodelling. But they cannot locate the problems of immutable loss of cardiac tissues. In this case, stem cell treatment holds a promising challenge. Stem cells are the cells that are capable of differentiating into many cells according to their needs. So, it is assumed that these cells can distinguish into many cells and if these cells can be individualized into cardiac cells then they can be used to replace the damaged tissues of the heart. There is some abridgment in this therapy, none the less stem cell therapy remains a hopeful destination in the treatment of heart disease. Elsevier 2022-09 2022-06-22 /pmc/articles/PMC9563042/ /pubmed/36249945 http://dx.doi.org/10.1016/j.jsps.2022.06.017 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Mahmud, Shabnur
Alam, Safaet
Emon, Nazim Uddin
Boby, Umme Habiba
Kamruzzaman
Ahmed, Firoj
Monjur-Al-Hossain, A.S.M.
Tahamina, Afroza
Rudra, Sajib
Ajrin, Marzina
Opportunities and challenges in stem cell therapy in cardiovascular diseases: Position standing in 2022
title Opportunities and challenges in stem cell therapy in cardiovascular diseases: Position standing in 2022
title_full Opportunities and challenges in stem cell therapy in cardiovascular diseases: Position standing in 2022
title_fullStr Opportunities and challenges in stem cell therapy in cardiovascular diseases: Position standing in 2022
title_full_unstemmed Opportunities and challenges in stem cell therapy in cardiovascular diseases: Position standing in 2022
title_short Opportunities and challenges in stem cell therapy in cardiovascular diseases: Position standing in 2022
title_sort opportunities and challenges in stem cell therapy in cardiovascular diseases: position standing in 2022
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9563042/
https://www.ncbi.nlm.nih.gov/pubmed/36249945
http://dx.doi.org/10.1016/j.jsps.2022.06.017
work_keys_str_mv AT mahmudshabnur opportunitiesandchallengesinstemcelltherapyincardiovasculardiseasespositionstandingin2022
AT alamsafaet opportunitiesandchallengesinstemcelltherapyincardiovasculardiseasespositionstandingin2022
AT emonnazimuddin opportunitiesandchallengesinstemcelltherapyincardiovasculardiseasespositionstandingin2022
AT bobyummehabiba opportunitiesandchallengesinstemcelltherapyincardiovasculardiseasespositionstandingin2022
AT kamruzzaman opportunitiesandchallengesinstemcelltherapyincardiovasculardiseasespositionstandingin2022
AT ahmedfiroj opportunitiesandchallengesinstemcelltherapyincardiovasculardiseasespositionstandingin2022
AT monjuralhossainasm opportunitiesandchallengesinstemcelltherapyincardiovasculardiseasespositionstandingin2022
AT tahaminaafroza opportunitiesandchallengesinstemcelltherapyincardiovasculardiseasespositionstandingin2022
AT rudrasajib opportunitiesandchallengesinstemcelltherapyincardiovasculardiseasespositionstandingin2022
AT ajrinmarzina opportunitiesandchallengesinstemcelltherapyincardiovasculardiseasespositionstandingin2022